视觉化加多运输穿越血脑屏障沿着周围血管清除通路
Svea Seehafer1, Yvonne Mrosek2, Lars-Patrick Schmill2
1Department of Radiology and Neuroradiology, University Hospital of Schleswig-Holstein, Kiel, Germany. svea.seehafer@uksh.de.
European radiology experimental
|February 4, 2026
概括
基于加多的对比剂 (GBCA) 运输发生在血液-大脑屏障 (BBB) 在数字减去血管造影 (DSA) 后被破坏的患者的周围血管空间. 这表明GBCA可能利用淋巴管道进行大脑清除.
科学领域:
- 神经成像是一种神经成像.
- 血管神经学 血管神经学
- 大脑生理学 脑生理学
背景情况:
- 血脑屏障 (BBB) 保护大脑,但在像数字减去血管造影 (DSA) 这样的手术后,其破坏可能发生.
- 淋巴系统对于大脑的废物清除至关重要,涉及沿周血管空间运输液体.
- 了解GBCA在受损BBB中的运输对于解释神经成像研究至关重要.
研究的目的:
- 为了研究基于加多的对比剂 (GBCA) 穿越血脑屏障 (BBB) 沿周围血管空间的运输.
- 评估GBCA运动作为淋巴排水的一部分,在DSA后的阳性BBB干扰患者中评估.
- 为了将GBCA外流模式与周血管空间和淋巴管路径相关联.
主要方法:
- 对43名接受DSA治疗内动脉瘤的患者的回顾性分析,在24小时内进行MRI.
- 评估BBB破坏使用前后对比3DT1加权MRI序列.
- 在T2加权序列上,GBCA增强模式与周血管空间的相关性;使用费舍尔精确测试和后勤回归进行统计分析.
主要成果:
- 43名患者中有30名 (69.8%) 显示出可见的BBB破坏,在治疗DSA后更频繁 (p=0.004).
- GBCA增强主要发生在皮肤表面 (96.7%) 和周围血管空间 (56.7%) 上.
- 增强模式遵循探测船只的下游领土,表明淋巴体运输参与.
结论:
- 这项研究提供了体内证据,表明GBCA在经过阳性BBB干扰后沿周血管空间运输,这可能反映了淋巴管道.
- 观察到的GBCA增强模式表明,从大脑表面到脑下关节空间的循序渐进通过周围血管路径.
- 研究结果强调了BBB完整性在神经血管健康中的作用,并提供了对大脑清除机制和诊断成像的见解.
相关概念视频
00:49The Blood-brain Barrier
53.1K
Overview
53.1K
01:14Hepatic Drug Clearance: Role of Transporters
310
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
310
01:22Photoreceptors and Visual Pathways
9.3K
At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category,...
9.3K
01:27Oxygen Transport in the Blood
6.7K
Hemoglobin (Hb) is a crucial molecule in the human body, consisting of four polypeptide chains, each bound to an iron-containing heme group. This unique structure enables hemoglobin to bind to oxygen, with each molecule capable of combining with four molecules of oxygen, leading to rapid and reversible oxygen loading. When fully loaded with oxygen, it is called oxyhemoglobin, while hemoglobin that has released oxygen is called reduced hemoglobin or deoxyhemoglobin. As hemoglobin binds oxygen,...
6.7K
01:19Carbon Dioxide Transport in the Blood
5.2K
Carbon dioxide (CO2) transport in the blood is critical to human physiology. On average, our body cells produce around 200 mL of CO2 per minute, precisely the quantity expelled by the lungs. This process involves the transportation of CO2 from the tissue cells to the lungs in three primary forms.
Forms of CO2 Transport
1. Dissolved in plasma: A small percentage (7-10%) of CO2 is transported and dissolved directly in the plasma.
2. Carbaminohemoglobin: Just over 20% of CO2 is chemically bound to...
Forms of CO2 Transport
1. Dissolved in plasma: A small percentage (7-10%) of CO2 is transported and dissolved directly in the plasma.
2. Carbaminohemoglobin: Just over 20% of CO2 is chemically bound to...
5.2K
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
299
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
299